SCHEMBL4628705

SCHEMBL4628705

CCOC(=O)C(CC(=O)O)NC(=O)CN

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
CAD P27708 1/20 0.42
NOD1 Q9Y239 3/20 0.39
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
PPID Q08752 1/20 0.35
CTSC P53634 1/20 0.34
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.33
P2RY12 Q9H244 1/20 0.33
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4628713 1.00 L3MBTL1 (0.46) L3MBTL1KMT2APOLBCADNOD1
SCHEMBL3868403 0.86 L3MBTL1 (0.54) L3MBTL1KMT2APOLBCADNOD1
SCHEMBL13253157 0.86 L3MBTL1 (0.54) L3MBTL1KMT2APOLBCADNOD1
SCHEMBL4629356 0.83 L3MBTL1 (0.59) L3MBTL1KMT2APOLBCADNOD1
SCHEMBL4629355 0.83 L3MBTL1 (0.59) L3MBTL1KMT2APOLBCADNOD1
SCHEMBL28322895 0.83 KMT2A (0.51) L3MBTL1KMT2APOLBCADNOD1
SCHEMBL28885651 0.83 KMT2A (0.51) L3MBTL1KMT2APOLBCADNOD1
SCHEMBL29543223 0.81 L3MBTL1 (0.47) L3MBTL1KMT2APOLBCADNOD1
SCHEMBL14951128 0.80 GNPAT (0.43) L3MBTL1KMT2APOLBCADCA2
SCHEMBL3861350 0.79 PPID (0.50) L3MBTL1KMT2APOLBCADPPID

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1618117-B1 TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF TRUSTEES EWHA WOMANS UNIVERSIT (KR) 2008-04-23 EP disclosed
EP-1618117-A4 TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF TRUSTEES EWHA WOMANS UNIVERSIT (KR) 2007-04-11 EP disclosed
EP-1618117-A1 TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF Board of Trustees, Ewha Womans University (KR) 2006-01-25 EP disclosed
US-6951953-B2 Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof EWHA WOMANS UNIVERSITY (KR) 2005-10-04 US disclosed
WO-2004096820-A1 TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF BOARD OF TRUSTEES, EWHA WOMANS UNIVERSITY (KR) 2004-11-11 WO disclosed
US-20040219127-A1 Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof EWHA WOMANS UNIVERSITY (KR) 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040219127-A1 Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof PHOSPHO1, FOLR1, PCNA L3MBTL1 1674/4885KMT2A 1444/4885POLB 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.